Biogen(BIIB)

CAMBRIDGE, MABiotechnology1 H-1B visas (FY2023)

View 254 open jobs Website LinkedIn Careers Page

Focus: Biogen is a $9.8B revenue large-cap biotechnology company headquartered in Cambridge, MA, with a dominant portfolio in neuroscience, rare diseases, and immunology. The company employs 7,500 and maintains significant scale in small molecules, biologics, biosimilars, and antisense oligonucleotides (ASO).

Neuroscience Rare Diseases Immunology

Profile data last refreshed 6h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

7,500

Open Jobs

254-5 this month

Cooling — net -5 jobs in 30d

111 added, 116 removed. Slower than typical.

Recent layoff filing — 172 affected

3/3/2026 — Shelby County, TN · 172 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Biogen?

AI assessment

Biogen offers stable career footing in a cash-generative organization with meaningful pipeline optionality, but job security is tempered by patent cliff exposure and demonstrated restructuring history.

Why Work Here

Market leader in MS with diversified peak-revenue franchises (TECFIDERA $235M, VUMERITY $152M, AVONEX $139M) generating stable cash flow for R&D reinvestment

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$9.8B

Key Products

TECFIDERA

Multiple Sclerosis, Relapsing-Remitting

$235M (Part D)

Peak9.5yr

Help build intelligence for Biogen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Multicenter Observational Study of Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

N/A

Clinical Trials (1)

NCT02308657Multicenter Observational Study of Myotonic Dystrophy Type 1

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Outpatient Muscle Biopsy

Sarcopenia

N/A

Clinical Trials (1)

NCT02839460A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy

N/A

Systemic Sclerosis Clinical and Biomarker Study

Healthy

N/A

Clinical Trials (1)

NCT02531009Systemic Sclerosis Clinical and Biomarker Study

N/A

Genomic Translation for Amyotrophic Lateral Sclerosis Care

ALS

N/A

Clinical Trials (1)

NCT02795897Genomic Translation for Amyotrophic Lateral Sclerosis Care

N/A

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Progressive Multifocal Leukoencephalopathy

N/A

Clinical Trials (1)

NCT01211639Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

N/A

This is a registry.

Dementia Disorder

N/A

MR Imaging

Healthy

N/A

Clinical Trials (1)

NCT03218111Glymphatic Kinetics In Healthy Adult Volunteers

N/A

Assessments

Frontotemporal Dementia

N/A

Clinical Trials (2)

NCT03088956Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

N/A

NCT04926129Natural History of the Progression of X-Linked Retinitis Pigmentosa

N/A

Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

Arthritis, Rheumatoid

N/A

Clinical Trials (1)

NCT01211678Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

N/A

Instrumented Data Exchange for Ataxia Study

Spinocerebellar Ataxia Type 1

N/A

Clinical Trials (1)

NCT04268147Instrumented Data Exchange for Ataxia Study

N/A

Colonoscopy

N/A

TruBeet inorganic beetroot juice

Nitrate

N/A

Clinical Trials (1)

NCT06602921The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function.

N/A

Functional MRI in Lupus Nephritis

Healthy

N/A

Clinical Trials (1)

NCT01731054Functional MRI in Lupus Nephritis

N/A

Lumbar puncture

Spinocerebellar Ataxia Type 2

N/A

Clinical Trials (1)

NCT04288128Integrated Functional Evaluation of the Cerebellum

N/A

No Intervention

Choroideremia

N/A

Clinical Trials (4)

NCT04750785A Study to Assess Choroideremia (CHM) Health Outcomes

N/A

NCT04795206Natural Disease Progression in Participants With Choroideremia

N/A

Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic

Myotonic Dystrophy 1

N/A

Clinical Trials (1)

NCT06089018Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy

N/A

Adult Spinal Muscular Atrophy (SMA) China Registry

Muscular Atrophy, Spinal

N/A

Clinical Trials (1)

NCT05618379Adult Spinal Muscular Atrophy (SMA) China Registry

N/A

A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects W

Mild Cognitive Impairment

N/A

Clinical Trials (1)

NCT02778438A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

N/A

Psychometric Validation of Cognitive Endpoints

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01335633Psychometric Validation of Cognitive Endpoints

N/A

Tysabri

Relapsing-Remitting Multiple Sclerosis

N/A

Clinical Trials (5)

NCT00744679A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

Phase 4

NCT01591551NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

Evaluation of Brain Atrophy in CIS Patients on Avonex

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01592474Evaluation of Brain Atrophy in CIS Patients on Avonex

N/A

natalizumab

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02137109Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

N/A

Scan-Rescan Sub-Study of MS PATHS

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT04123353Scan-Rescan Sub-Study of MS PATHS

N/A

Tysabri

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01071512Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

N/A

natalizumab

Relapsing-Remitting Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01485003Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

N/A

Tysabri®

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01070823JC-Virus (JCV) Antibody Program

N/A

dimethyl fumarate

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02047097Dimethyl Fumarate (DMF) Observational Study

N/A

ThecaFlex DRx System

Spinal Muscular Atrophy

N/A

Clinical Trials (1)

NCT05866419Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

N/A

SC Peginterferon beta-1a

Multiple Sclerosis, Relapsing-Remitting

N/A

Clinical Trials (1)

NCT03347370A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis

N/A

peginterferon beta-1a

Relapsing Forms of Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02230969Plegridy Observational Program

N/A

DigiCog

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT04756700Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis

N/A

Skin Taping

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT02125695Pilot Tape Harvesting Study

N/A

Interferon beta-1a

Multiple Sclerosis

N/A

Clinical Trials (5)

NCT00915460Open-Label Safety Extension Study of Avonex

Phase 4

NCT00574041How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Phase 4

Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Va

Multiple Sclerosis (MS)

N/A

Clinical Trials (1)

NCT05197699Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study

N/A

Omaveloxolone

Friedreich Ataxia

N/A

Clinical Trials (1)

NCT06628687A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

N/A

Natalizumab

Relapsing-Remitting Multiple Sclerosis (RRMS)

N/A

Clinical Trials (1)

NCT05304520A Study for Tysabri Participant Preference

N/A

Avonex® monotherapy

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00463710Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

N/A

Multiple Sclerosis Performance Test

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT03926637Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

N/A

Konectom platform

Multiple Sclerosis (MS)

N/A

Clinical Trials (1)

NCT05106465A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

N/A

Risdiplam

Spinal Muscular Atrophy (SMA)

N/A

Clinical Trials (1)

NCT06978985Adult SMA Research and Clinical Hub

N/A

Dimethyl fumarate

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01911767Biogen Multiple Sclerosis Pregnancy Exposure Registry

N/A

natalizumab

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02386566Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

N/A

Natural History of the Progression of Choroideremia Study

Choroideremia

N/A

Clinical Trials (1)

NCT03359551Natural History of the Progression of Choroideremia Study

N/A

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Optic Neuritis

N/A

Biopsy

Healthy

N/A

Clinical Trials (1)

NCT02422407A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

N/A

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cogniti

Healthy

N/A

Clinical Trials (1)

NCT02283918Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

N/A

An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguis

Mild Cognitive Impairment

N/A

Clinical Trials (1)

NCT05058950An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging

N/A

MS PATHS Normative Sub-Study

Healthy Volunteer

N/A

Clinical Trials (1)

NCT02996084MS PATHS Normative Sub-Study

N/A

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multipl

Exercise

N/A

Clinical Trials (1)

NCT01065090A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis

N/A

Interview Prep Quick Facts

Portfolio: 24 approved products, 154 clinical trials

Top TAs: Neurology, Oncology, Immunology

H-1B (2023): 1 approval

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 254 active jobs

Portfolio Health

Growth2 (8%)

Peak8 (33%)

LOE Approaching3 (13%)

Post-LOE11 (46%)

24 total products

Therapeutic Area Focus

Neurology

22 marketed304 pipeline

Oncology

3 marketed57 pipeline

Immunology

3 marketed47 pipeline

Rare Diseases

3 marketed28 pipeline

Financials (FY2025)

Revenue

$9.8B3%

R&D Spend

$2.4B(25%)10%

Net Income

$1.2B

Hiring Trend

Stable

254

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2024-03-25

1,000 employees affected— Cambridge, MA

Source: state DOL filings, aggregated via Big Local News

1,000 employee reduction in Cambridge, MA (March 2024) following Aduhelm restructuring signals vulnerability to clinical failures and portfolio decisions.

Recent large-scale layoff demonstrates organization's willingness to restructure aggressively post-setback; job security is performance-dependent and program-dependent rather than tenure-based.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Impact of Treatment Effect Heterogeneity on the Estimation of Individualized Treatment Rules for Count Outcomes.

Biometrical journal. Biometrische Zeitschrift

2026

PMID:41814679

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom.

12.1 Mechanism of Action The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown. 12.2 Pharmacodynamics There is no biochemical or physiologic effect known to relate directly to the clinical effect of PLEGRIDY. 12.3 Pharmacokinetics After single-dose or multiple-dose subcutaneous administration of PLEGRIDY to healthy subjects, serum PLEGRIDY peak concentration (C max ) and total exposure over time (area under the curve, or AUC) increased in proportion to doses from 63 to 188 micrograms. PLEGRIDY did not accumulate in the serum after multiple doses of 125 micrograms every 14 days. Pharmacokinetic parameters for PLEGRIDY, including C max and AUC, did not differ significantly between healthy volunteers and multiple sclerosis patients or between single-dose and multiple-dose administrations. However, the coefficient of variation between individual patients for AUC, C max , and half-life was high (41% to 68%, 74% to 89%, and 45% to 93%, respectively). Absorption After 125 microgram subcutaneous doses of PLEGRIDY in multiple sclerosis patients, the maximum concentration occurred between 1 and 1.5 days, the mean C max was 280 pg/mL, and the AUC over the 14 day dosing interval was 34.8 ng.hr/mL. Distribution In multiple sclerosis patients taking 125 microgram subcutaneous doses of PLEGRIDY every 14 days, the estimated volume of distribution was 481 liters. Metabolism and Elimination Clearance mechanisms for PLEGRIDY include catabolism and excretion. The major pathway of elimination is renal. The half-life is approximately 78 hours in multiple sclerosis patients. The mean steady state clearance of PLEGRIDY is approximately 4.1 L/hr. PLEGRIDY is not extensively metabolized in the liver. The pharmacokinetics of 125 μg single dose of PLEGRIDY administered subcutaneously and intramuscularly were similar. Specific Populations Body weight, gender, and age do not require dosage adjustment. Renal impairment can increase the C max and AUC for PLEGRIDY. Results of a pharmacokinetic study in patients with mild, moderate, and severe renal impairment (creatinine clearance 50 to 80, 30 to 50, and less than 30 mL/minute, respectively) showed increases above normal for C max of 27%, 26%, and 42%, and for AUC, increases of 30%, 40%, and 53%. The half-life was 53, 49, and 82 hours in patients with mild, moderate, and severe renal impairment, respectively, compared to 54 hours in normal subjects. In the same study, subjects with end stage renal disease requiring hemodialysis two or three times weekly had AUC and C max of PLEGRIDY values that were similar to those of normal controls. Each hemodialysis session removed approximately 24% of circulating PLEGRIDY from the systemic circulation [see Use in Specific Populations ( )] .

Biogen(BIIB)

Should You Work at Biogen?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (12)

Key Products by Revenue

Other Products (5)

Pipeline & Clinical Trials

Open Jobs (254)

RTR Senior Analyst

Graduate, Marketing

Senior Medical Manager

Sr Tech I, Instrumentation & Controls

Senior Manager, Patient Centricity and Engagement Lead

Senior Market Access Manager - Saudi Arabia

Associate Director, Neuropsychiatry Market Access Strategy

Sr Manager, Business Insights & Analytics, Rare Disease

Senior Medical Science Liaison

Pasantia - Patient Centricity

Lead, Manufacturing Associate Oligonucleotide Synthesis

Facilities Technician III (Nights)

Business Development Counsel

Senior Manager, Device Quality Systems

Sr Principal Analyst, Statistical Programming

Patient Advocacy Lead - LAN

Manager, Device Quality Systems

Associate Director, PV Scientist

Intern, Manufacturing Specialist

Co-op, Video Production and Digital Content

Sr. Finance Business Partner

Sr. Analyst, Statistical Programming

Principal Analyst, Statistical Programming

Gerente de Área de Negócios - Brasília/DF

Communications and Events Manager

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Research Publications(10)